文献速递妇科

IB1期宫颈癌中范围较小与范围较大的根治性手术比较:一项基于人群的长期生存研究

Less versus more radical surgery in stage IB1 cervical cancer: A population-based study of long-term survival.
PubMed 文献 · Gynecol Oncol · 2018-01-01

基于SEER数据库纳入1998年1月至2012年12月诊断的45岁以下FIGO IB1期宫颈癌且接受淋巴结评估的2571例患者,其中807例接受范围较小手术(LRS),1764例接受范围较大手术(MRS)。中位随访79个月,LRS与MRS的10年疾病特异性生存率分别为93.5%与92.3%(p=0.511),按肿瘤大小分层后两组间亦无显著差异。作者认为在经选择的年轻IB1期宫颈癌患者中,LRS与MRS相比似乎不损害疾病特异性生存。

要点

  • 45岁以下IB1期宫颈癌且接受淋巴结评估者中,LRS与MRS的10年疾病特异性生存率分别为93.5%与92.3%(p=0.511)。
  • 肿瘤≤2 cm者10年疾病特异性生存率LRS 95.1% vs MRS 95.6%(p=0.80),肿瘤>2 cm者LRS 90.1% vs MRS 88.2%(p=0.48)。
  • 腺鳞癌(HR 2.37)、G3疾病(HR 2.86)、肿瘤>2 cm(HR 1.82)及淋巴结阳性(HR 2.42)与死亡风险升高独立相关。

核心结论

  • 在经选择的年轻IB1期宫颈癌患者中,与MRS相比,LRS似乎不损害疾病特异性生存。

研究设计与样本

  • 基于监测、流行病学和最终结果(SEER)数据库的人群研究,纳入1998年1月至2012年12月诊断的45岁以下FIGO IB1期宫颈癌女性,仅分析接受淋巴结评估者,共2571例,其中807例接受LRS(锥切、宫颈切除术、单纯子宫切除术),1764例接受MRS(改良根治性、根治性子宫切除术)。

主要发现

  • LRS组与MRS组分别有28%与23%诊断为腺癌(p=0.024),31%与39%为G3疾病(p<0.001),40%与45%肿瘤大小>2 cm(p<0.001),27%与29%接受辅助放疗(p=0.005)。
  • 中位随访79个月(范围0-179),LRS与MRS的10年疾病特异性生存率分别为93.5%与92.3%(p=0.511)。
  • 按肿瘤大小≤2 cm分层,10年疾病特异性生存率LRS 95.1% vs MRS 95.6%(p=0.80);按肿瘤大小>2 cm分层,LRS 90.1% vs MRS 88.2%(p=0.48)。
  • 与死亡风险升高独立相关的因素包括腺鳞癌(HR 2.37)、G3疾病(HR 2.86)、肿瘤>2 cm(HR 1.82)及淋巴结阳性(HR 2.42)。
  • 与MRS相比,LRS与死亡风险升高无关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Standard surgical treatment for women with stage IB1 cervical cancer consists of radical hysterectomy. This study assesses survival outcomes of those treated with less radical surgery (LRS; conization, trachelectomy, simple hysterectomy) compared to more radical surgery (MRS; modified radical, radical hysterectomy). METHODS: Using the Surveillance, Epidemiology and End Results database, we identified women <45 years with FIGO stage IB1 cervical cancer diagnosed from 1/1998 to 12/2012. Only those who underwent lymph node (LN) assessment were analyzed. Disease-specific survivals (DSSs) of LRS were compared with those of MRS. RESULTS: Of 2571 patients, 807 underwent LRS and 1764 underwent MRS, all with LN assessment. For LRS vs. MRS, 28% vs. 23% were diagnosed with adenocarcinoma (p = 0.024), 31% vs. 39% had G3 disease (p < 0.001), 40% vs. 45% had tumor size >2 cm (p < 0.001), and 27% vs. 29% received adjuvant radiation therapy (p = 0.005). Median follow-up was 79 months (range, 0-179). Ten-year DSS for LRS vs. MRS was 93.5% vs. 92.3% (p = 0.511). There was no difference in 10-year DSS when stratified by tumor size ≤2 cm (LRS 95.1% vs. MRS 95.6%, p = 0.80) or > 2 cm (LRS 90.1% vs. MRS 88.2%, p = 0.48). Factors independently associated with increased risk of death included adenosquamous histology (HR 2.37), G3 disease (HR 2.86), tumors >2 cm (HR 1.82), and LN positivity (HR 2.42). Compared to MRS, LRS was not associated with a higher risk of death. CONCLUSIONS: In a select group of young women with stage IB1 cervical cancer, LRS compared to MRS does not appear to compromise DSS.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Tseng JH, Aloisi A, Sonoda Y, et al. Less versus more radical surgery in stage IB1 cervical cancer: A population-based study of long-term survival. Gynecol Oncol. 2018. PMID: 29776598. doi:10.1016/j.ygyno.2018.04.571

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。